Production (Stage)
Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.75M | 7.93M | 6.97M | 7.26M | 25.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.75M | 7.93M | 6.97M | 7.26M | 25.38M |
| Cost of Revenue | 373.00K | 669.00K | 1.36M | 608.00K | 550.00K |
| Gross Profit | 8.38M | 7.26M | 5.62M | 6.65M | 24.83M |
| SG&A Expenses | 9.09M | 8.14M | 10.72M | 11.54M | 11.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.56M | 8.86M | 12.18M | 12.30M | 11.63M |
| Operating Income | -808.00K | -934.00K | -5.20M | -5.04M | 13.74M |
| Income Before Tax | -1.17M | -1.62M | -5.74M | -5.55M | 12.84M |
| Income Tax Expenses | -- | 365.00K | -- | -- | -- |
| Earnings from Continuing Operations | -1.17M | -1.99M | -5.74M | -5.55M | 12.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.17M | -1.99M | -5.74M | -5.55M | 12.84M |
| EBIT | -808.00K | -934.00K | -5.20M | -5.04M | 13.74M |
| EBITDA | -782.00K | -909.00K | -5.18M | -5.01M | 14.47M |
| EPS Basic | -0.04 | -0.07 | -0.21 | -0.20 | 0.47 |
| Normalized Basic EPS | -0.03 | -0.04 | -0.13 | -0.13 | 0.30 |
| EPS Diluted | -0.04 | -0.08 | -0.21 | -0.20 | 0.41 |
| Normalized Diluted EPS | -0.03 | -0.04 | -0.13 | -0.13 | 0.26 |
| Average Basic Shares Outstanding | 27.58M | 27.46M | 27.37M | 27.30M | 27.05M |
| Average Diluted Shares Outstanding | 27.58M | 27.46M | 27.37M | 27.30M | 31.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |